Amwell reported Q3 2026 revenue of $49 million, surpassing guidance, with subscription revenue at $23.9 million and medical group visits at 0.8 million. Despite a net loss of $11 million, the company raised its 2026 revenue forecast to $204-$206 million and adjusted EBITDA to between -$8 million and -$7 million. Amwell expects positive operational cash flow in Q4 2026, signaling progress toward profitability. The company continues to focus on its integrated healthcare platform and AI-powered care solutions.
Amwell's Q3 2026 revenue reached $49 million, exceeding guidance, with a net loss of $11 million but an optimistic forecast for 2026 revenue and EBITDA. For readers following the health sector, here is Pluang's market snapshot as of Nov 04, 2026 04:11 WIB: out of 150 priced US health stocks, 92 rose and 55 fell. Notable movers include SMMT at USD 15.86 (+7.09%, 0% Sell / 100% Buy, typical hold time 18 days), TNGX at USD 23.17 (+6.48%, typical hold time 4 days), and TXG at USD 65.43 (+6.17%, 40% Sell / 60% Buy, typical hold time 92 days).
Nova Klúbburinn hf. has completed a share buyback program, acquiring 122,699,386 shares at an average price of ISK 3.26 per share. The buyback was part of an inverse offer process with valid bids for 159,526,476 shares. The company accepted bids up t...
AMC Entertainment will release its Q3 2026 earnings on Nov. 4, following a year-over-year increase in North American box-office receipts to about $3.1 billion from $2.5 billion in Q3 2025. The quarter featured major film releases like Spider-Man: Bra...
Pomerantz LLP is investigating Erasca, Inc. following the termination of its COO, Nicholas Chetwyn, which led to a nearly 10% drop in the company's stock price. The investigation focuses on whether Erasca and its executives engaged in securities frau...
Pomerantz LLP is investigating claims against Yiren Digital Ltd. for possible securities fraud following the company's disclosure of a 34% revenue decline and a significant net loss in Q4 2025. The company also reported increased delinquency rates an...
Pomerantz LLP is investigating Syndax Pharmaceuticals following the company's announcement that its Phase 2 trial for axatilimab in idiopathic pulmonary fibrosis failed to meet its primary endpoint. This news caused Syndax's stock to drop by 2.59% on...
